Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Kidney Disease and Beyond DOI Creative Commons
Zein Alabdin Hannouneh, Carmen Elena Cervantes,

Mohamad Hanouneh

и другие.

Glomerular Diseases, Год журнала: 2025, Номер 5(1), С. 119 - 132

Опубликована: Янв. 23, 2025

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have significantly impacted the management of diabetic kidney disease (DKD) and heart failure (HF), providing benefits beyond glycemic control. This review examines mechanisms through which SGLT2is provide renal cardiovascular protection assesses their clinical efficacy. Summary: By inducing glucosuria natriuresis, alleviate multiple complications induced by chronic hyperglycemia. Moreover, reduce albuminuria, improve tubular function, modulate erythropoiesis. Additionally, they mitigate inflammation fibrosis decreasing oxidative stress downregulating proinflammatory pathways. Clinical trials demonstrated significant reductions in events among patients with type diabetes mellitus. A comprehensive literature was conducted PubMed, highlighting effects results major involving SGLT2is. Key Messages: play a crucial role DKD HF addressing pathogenic Currently, are included guidelines for management, extend to nondiabetic populations. Further research is needed explore SGLT2is’ multifaceted potential applications across diverse patient populations different etiologies.

Язык: Английский

Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Kidney Disease and Beyond DOI Creative Commons
Zein Alabdin Hannouneh, Carmen Elena Cervantes,

Mohamad Hanouneh

и другие.

Glomerular Diseases, Год журнала: 2025, Номер 5(1), С. 119 - 132

Опубликована: Янв. 23, 2025

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have significantly impacted the management of diabetic kidney disease (DKD) and heart failure (HF), providing benefits beyond glycemic control. This review examines mechanisms through which SGLT2is provide renal cardiovascular protection assesses their clinical efficacy. Summary: By inducing glucosuria natriuresis, alleviate multiple complications induced by chronic hyperglycemia. Moreover, reduce albuminuria, improve tubular function, modulate erythropoiesis. Additionally, they mitigate inflammation fibrosis decreasing oxidative stress downregulating proinflammatory pathways. Clinical trials demonstrated significant reductions in events among patients with type diabetes mellitus. A comprehensive literature was conducted PubMed, highlighting effects results major involving SGLT2is. Key Messages: play a crucial role DKD HF addressing pathogenic Currently, are included guidelines for management, extend to nondiabetic populations. Further research is needed explore SGLT2is’ multifaceted potential applications across diverse patient populations different etiologies.

Язык: Английский

Процитировано

0